$474.62
1.94% yesterday
Nasdaq, Apr 04, 10:09 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$474.62
-11.60 2.39% 1M
+19.31 4.24% 6M
+71.92 17.86% YTD
+70.61 17.48% 1Y
+205.98 76.68% 3Y
+219.32 85.91% 5Y
+356.37 301.37% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-9.39 1.94%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $121.88b
Enterprise Value $117.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.70
P/S ratio (TTM) P/S ratio 11.10
P/B ratio (TTM) P/B ratio 7.43
Revenue growth (TTM) Revenue growth 11.64%
Revenue (TTM) Revenue $10.98b
EBIT (operating result TTM) EBIT $-181.60m
Free Cash Flow (TTM) Free Cash Flow $-790.30m
Cash position $6.12b
EPS (TTM) EPS $-2.20
P/E forward 29.49
P/S forward 10.18
EV/Sales forward 9.82
Short interest 2.24%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

20x Buy
57%
13x Hold
37%
2x Sell
6%

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
57%
Hold
37%
Sell
6%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10,984 10,984
12% 12%
100%
- Direct Costs 1,531 1,531
21% 21%
14%
9,454 9,454
10% 10%
86%
- Selling and Administrative Expenses 1,259 1,259
32% 32%
11%
- Research and Development Expense 8,171 8,171
123% 123%
74%
24 24
99% 99%
0%
- Depreciation and Amortization 206 206
14% 14%
2%
EBIT (Operating Income) EBIT -182 -182
105% 105%
-2%
Net Profit -536 -536
115% 115%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Investors Business Daily
about 16 hours ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
The Motley Fool
about 23 hours ago
Which group of individuals is in the best position to spot early warning signs of economic trouble? There's a good case to be made for corporate chief financial officers (CFOs).
Neutral
CNBC
4 days ago
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today